The Molecular Pathogenesis and Clinical Implications of Hepatocellular Carcinoma

Table 2

Ongoing clinical trials using molecular-targeted agents for hepatocellular carcinoma.

Acronym	Phase	Active arm	Control arm	Design of the clinical trials
STORM	III	Sorafenib	Placebo	Adjuvant therapy after resection or ablation
SILIUS	III	Sorafenib + TACI	Sorafenib	Combination therapy with hepatic arterial infusion chemotherapy (TACI)
SPACE	II	Sorafenib + TACE	Placebo + TACE	Combination therapy with transarterial chemoembolization (TACE)
TACTICS	II	Sorafenib + TACE	TACE alone	Combination therapy with transarterial chemoembolization (TACE)
BRISK-PS	III	Brivanib	Placebo	Second-line therapy in sorafenib-resistant HCC
BRISK-TA	III	Brivanib + TACE	Placebo + TACE	Combination therapy with transarterial chemoembolization (TACE)
BRISK-FL	III	Brivanib	Sorafenib	First-line clinical trial for brivanib versus sorafenib